What is Lantern Pharma?
Headquartered in Dallas, Texas, Lantern Pharma operates at the intersection of computational biology and clinical oncology. The company utilizes its RADR platform—a sophisticated engine powered by machine learning and genomics—to streamline the development of small molecule drug candidates. Through its subsidiary, Starlight Therapeutics, the organization is actively advancing an antibody-drug conjugate program, aiming to reduce the time and cost associated with bringing life-saving cancer treatments to market. By leveraging large-scale datasets, Lantern Pharma effectively de-risks the drug development lifecycle, positioning itself as a critical player in the next generation of precision medicine.
How much funding has Lantern Pharma raised?
Lantern Pharma has raised a total of $8.1M across 2 funding rounds:
Series A
$3.7M
Stock/Share Issuance
$4.4M
Series A (2017): $3.7M with participation from GPG Ventures and Bios Partners
Stock/Share Issuance (2026): $4.4M, investors not publicly disclosed
Key Investors in Lantern Pharma
GPG Ventures
A Dallas-based venture capital firm specializing in medical-related start-ups, providing strategic solutions and growth capital to innovative healthcare ventures.
Bios Partners
A venture capital firm focused on bringing advanced biotech innovations to market, with a specific emphasis on overlooked scientific opportunities across the Central U.S.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lantern Pharma?
With the recent influx of capital, Lantern Pharma is poised to accelerate its clinical pipeline and expand the capabilities of its RADR platform. The strategic focus will likely shift toward scaling its antibody-drug conjugate program and deepening its genomic insights to identify new therapeutic targets. As the company transitions into more advanced clinical phases, the emphasis will remain on maintaining operational efficiency while navigating the regulatory landscape of oncology drug development. This financial runway provides the necessary resources to sustain long-term research initiatives and potentially secure further partnerships within the global biopharmaceutical ecosystem.
See full Lantern Pharma company page
